Applications of Cannabinoids in Neuropathic Pain: An Updated Review.
Journal
Critical reviews in therapeutic drug carrier systems
ISSN: 2162-660X
Titre abrégé: Crit Rev Ther Drug Carrier Syst
Pays: United States
ID NLM: 8511159
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
2
11
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
ppublish
Résumé
Neuropathic pain is experienced due to injury to the nerves, underlying disease conditions or toxicity induced by chemotherapeutics. Multiple factors can contribute to neuropathic pain such as central nervous system (CNS)-related autoimmune and metabolic disorders, nerve injury, multiple sclerosis and diabetes. Hence, development of pharmacological interventions to reduce the drawbacks of existing chemotherapeutics and counter neuropathic pain is an urgent unmet clinical need. Cannabinoid treatment has been reported to be beneficial for several disease conditions including neuropathic pain. Cannabinoids act by inhibiting the release of neurotransmitters from presynaptic nerve endings, modulating the excitation of postsynaptic neurons, activating descending inhibitory pain pathways, reducing neural inflammation and oxidative stress and also correcting autophagy defects. This review provides insights on the various preclinical and clinical therapeutic applications of cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN) in various diseases and the ongoing clinical trials for the treatment of chronic and acute pain with cannabinoids. Pharmacological and genetic experimental strategies have well demonstrated the potential neuroprotective effects of cannabinoids and also elaborated their mechanism of action for the therapy of neuropathic pain.
Identifiants
pubmed: 37824417
pii: 7ec6441519bff684,786cb61f3f1ec955
doi: 10.1615/CritRevTherDrugCarrierSyst.2022038592
doi:
Substances chimiques
Cannabinoids
0
Cannabidiol
19GBJ60SN5
Cannabinol
7UYP6MC9GH
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-33Subventions
Organisme : NIMHD NIH HHS
ID : U54 MD007582
Pays : United States